Staging early Alzheimer's disease progression in Down Syndrome using mixed clinical, biofluid and neuroimaging markers with machine learning
This study will refine the timings for cognitive testing, informant ratings, neuroimaging, and blood sampling to enhance understanding of AD progression in DS. The EBM offers individual-level staging which may enable earlier diagnosis, improve clinical trial design, and optimise biomarker use in this population. Combining modalities promises more insights into preclinical AD stages in DS.
Authors
- Leda Bianchi
- P. A. Wijeratne (ORCID: https://orcid.org/0000-0002-4885-6241)
- André Strydom (ORCID: https://orcid.org/0000-0002-2502-6704)
- Mina Idris (ORCID: https://orcid.org/0000-0002-8617-2908)
- Fedal Saini (ORCID: https://orcid.org/0000-0003-0104-1405)
- Jasmine Wells (ORCID: https://orcid.org/0000-0002-0327-116X)
- Henrik Zetterberg
- Phoebe Ivain
Institutions
- University of Sussex (GB)
- King's College London (GB)
- University of Gothenburg (SE)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_100350
- Primary Topic
- Down syndrome and intellectual disability research
- Type
- article
- Field-Weighted Citation Impact
- 0.00